Mass media

Press releases

International Health Forum: APMGR demands the withdrawal of abusive fiscal policies in the pharmaceutical sector

BUCHAREST, September 15th, 2015 - The Romanian Association of Generic Drug Manufacturers  (APMGR), representing generic drug manufacturing companies from Romania, demands that authorities withdraw abusive fiscal policies existing in the pharmaceutical field, in order to rebuild a sustainable base for the Romanian health system, in compliance with the recommendations issued by the European Commission


07.05.2014 - APMGR calls for more transparency in calculating the clawback tax by reporting the number of units settled by CNAS

BUCHAREST, May 7 2014- The Association of Generic Medicine Producers from Romania (APMGR) calls for more transparency in the calculation of the clawback tax contribution, given that the level of the contribution was maintained at a very high level, unsustainable for generic manufacturers


09.10.2013 - EGA's vision of the future for the generic and biosimilar medicine industries in europe

BRUSSELS, 9 October 2013 - On Tuesday 8th October, the European Generic medicines Association (EGA) launched its industrial policy vision for the future of the generic and biosimilar medicine industries in Europe at the EGA Industrial Policy Conference gathering together more than 80 participants with high level representatives from the pharmaceutical industry, EU policy makers, EU stakeholders and patients


01.07.2013 - A new era of biosimilar medicines is about to start: CHMP positive scientific opinion for first biosimilar monoclonal antibodies

BRUSSELS, 1 July 2013 - The EGA welcomes the European Medicines Agency’s recommendation to the European Commission to approve the first two infliximab biosimilar products, both referenced to Remicade©


13.06.2013 - Only increased focus on generic and biosimilar medicines can make european healthcare sustainable

ATHENS, 13 June 2013 - Addressing delegates at the 19th EGA Annual Conference in Athens, Gudbjorg Edda Eggertsdottir stressed that generic and biosimilar medicines companies ensuring high-quality manufacturing jobs and know-how should remain in Europe; benefiting society and patients and increasing the competitiveness and innovative capacity of our strategic industry